Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.
Luke Nordquist, MD
Advertisement
Articles by Luke Nordquist, MD
Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
Advertisement
Latest Updated Articles
Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPCSeptember 16th 2016
- Dr. Luke Nordquist on Who Should Receive Radium-223
October 20th 2016
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5